Free Trial

Disc Medicine (IRON) Stock Forecast & Price Target

Disc Medicine logo
$65.26 +0.30 (+0.46%)
(As of 08:01 PM ET)

Disc Medicine - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
10

Based on 10 Wall Street analysts who have issued ratings for Disc Medicine in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 9 have given a buy rating, and 1 has given a strong buy rating for IRON.

Consensus Price Target

$85.80
31.47% Upside
According to the 10 analysts' twelve-month price targets for Disc Medicine, the average price target is $85.80. The highest price target for IRON is $118.00, while the lowest price target for IRON is $70.00. The average price target represents a forecasted upside of 31.47% from the current price of $65.26.
Get the Latest News and Ratings for IRON and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Disc Medicine and its competitors.

Sign Up

IRON Analyst Ratings Over Time

TypeCurrent Forecast
11/26/23 to 11/25/24
1 Month Ago
10/27/23 to 10/26/24
3 Months Ago
8/28/23 to 8/27/24
1 Year Ago
11/26/22 to 11/26/23
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
9 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$85.80$66.40$64.13$59.22
Forecasted Upside31.47% Upside44.32% Upside29.68% Upside10.12% Upside
Consensus Rating
Buy
Moderate Buy
Moderate Buy
Buy

IRON Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IRON Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Disc Medicine Stock vs. The Competition

TypeDisc MedicineMedical CompaniesS&P 500
Consensus Rating Score
3.10
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside32.08% Upside27,006.30% Upside7.66% Upside
News Sentiment Rating
Positive News

See Recent IRON News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/13/2024HC Wainwright
2 of 5 stars
 Boost TargetBuy ➝ Buy$70.00 ➝ $118.00+89.95%
11/12/2024Wedbush
4 of 5 stars
 Reiterated RatingOutperform$75.00 ➝ $83.00+31.20%
11/5/2024Scotiabank
5 of 5 stars
G. Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Outperform ➝ Sector Outperform$62.00 ➝ $70.00+8.07%
11/5/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$85.00+45.92%
11/4/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Strong-Buy$66.00 ➝ $110.00+95.73%
10/23/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$89.00+74.78%
10/15/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$85.00 ➝ $85.00+77.23%
8/22/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Fauth
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$75.00+52.10%
6/17/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$50.00 ➝ $70.00+51.29%
4/8/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$71.00 ➝ $73.00+144.31%
4/24/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Katkhuda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/28/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$36.00+47.60%
2/28/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$36.00+47.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:23 PM ET.


IRON Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Disc Medicine is $85.80, with a high forecast of $118.00 and a low forecast of $70.00.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRON shares.

According to analysts, Disc Medicine's stock has a predicted upside of 31.47% based on their 12-month stock forecasts.

Over the previous 90 days, Disc Medicine's stock had 2 upgrades by analysts.

Disc Medicine has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group, Morgan Stanley, Raymond James, Scotiabank, and Wedbush in the past 90 days.

Analysts like Disc Medicine more than other "medical" companies. The consensus rating for Disc Medicine is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IRON compares to other companies.


This page (NASDAQ:IRON) was last updated on 11/25/2024 by MarketBeat.com Staff
From Our Partners